

# Advancements in Dermatological Applications of Curcumin: Clinical Efficacy and Mechanistic Insights in the Management of Skin Disorders

Zhiming Mo<sup>1</sup>, Jiayi Yuan<sup>1</sup>, Xuelian Guan<sup>1</sup>, Jianhong Peng<sup>2</sup>

<sup>1</sup>Department of Pharmaceutical Center, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People's Republic of China;

<sup>2</sup>Department of Internal Medicine, Dongguan Traditional Chinese Medicine Hospital, Dongguan, 523000, People's Republic of China

Correspondence: Jianhong Peng, Department of Internal Medicine, Dongguan Traditional Chinese Medicine Hospital, No. 3, Dongcheng Section, Songshan Lake Avenue, Dongcheng District, Dongguan, Guangdong Province, 523000, People's Republic of China, Tel +86 0769-22245614, Email pengjihzyy@outlook.com

**Abstract:** Curcumin, derived from *Curcuma longa* (turmeric), exhibits significant potential in dermatology, addressing conditions like atopic dermatitis, psoriasis, chronic wounds, skin cancer, and infections through its anti-inflammatory, antioxidant, anticancer, and antimicrobial properties. This review synthesizes evidence on curcumin's mechanisms, including modulation of immune responses and promotion of wound healing, showcasing its efficacy in reducing inflammation, cytokine levels, and enhancing skin barrier functions. Studies highlight curcumin's ability to selectively target tumor cells, suggesting a multifaceted approach to cancer therapy with minimal side effects. Despite promising therapeutic benefits, challenges remain in bioavailability, potency, and targeted delivery, underscoring the need for further research to optimize dosages, delivery methods, and assess long-term safety. The integration of curcumin into dermatological practice requires a balanced consideration of evidence-based efficacy and safety. Curcumin's comprehensive utility in dermatology, coupled with the necessity for advanced scientific exploration, emphasizes the importance of combining traditional knowledge with contemporary research to improve patient care in dermatology. This approach could significantly enhance outcomes for individuals with skin-related conditions, marking curcumin as a versatile and promising agent in the field.

**Keywords:** curcumin, atopic dermatitis, psoriasis, chronic wounds, skin cancer

## Introduction

The skin, as the body's largest organ, serves a crucial role in providing protection, acting as a barrier, regulating body temperature, and enabling sensation. However, nearly 80% of the adult population has experienced skin disorders in their lives, with more than one-third of individuals facing a three or more simultaneous conditions.<sup>1,2</sup> It poses significant challenges to the quality of life for both adults and teenagers, as lesions in visible areas can lead to emotional distress, including sadness, low self-esteem, and social withdrawal, which may further predispose individuals to psychiatric disorders.<sup>3,4</sup>

Curcumin (CUR), constituting 2 to 8% of the compounds in *Curcuma longa* (turmeric) and recognized as a potent polyphenol, is celebrated for its therapeutic efficacy in traditional Chinese medicine (TCM).<sup>5</sup> It was first identified about two centuries ago by Vogel and Pelletier, who reported isolating a "yellow coloring-matter" from the rhizomes of *Curcuma longa* (turmeric).<sup>6</sup> Moreover, it is a diferuloyl methane molecule [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], consisting of two ferulic acid residues linked by a methylene bridge, and is one of the main curcuminoids alongside demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC), which are commercially available.<sup>7</sup> Furthermore, it exhibits a broad spectrum of beneficial effects, encompassing anti-inflammatory,<sup>8</sup> antioxidant,<sup>9</sup> anticancer,<sup>10</sup> and antimicrobial properties.<sup>11</sup> The diverse impacts of CUR stem from its ability to engage with various molecules and to modulate numerous molecular pathways along with their targets.<sup>12</sup> These characteristics have established CUR as a potent remedy for an array of dermatological conditions.<sup>13</sup> Despite CUR's extensive

pharmacological benefits, its clinical use is limited by poor oral bioavailability and low stability; addressing these issues may involve structural modifications and innovative delivery systems to improve its properties and bioavailability.<sup>14,15</sup>

In recent years, many studies have validated that turmeric/CUR products and supplements, whether applied topically or taken orally, can offer therapeutic advantages for skin health.<sup>16,17</sup> This review aims to encapsulate the progress in CUR for treatment and management of skin disorders, offering insights that could guide both therapeutic practices and future clinical and foundational research in the realm of skin disorders.

## Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, relapsing, and remitting skin condition marked by persistent itching and non-infectious inflammation.<sup>18,19</sup> The worldwide prevalence of atopic dermatitis is estimated to be up to 10% in adults and between 15% and 20% in children.<sup>20,21</sup> The mechanism behind AD involves genetic and environmental factors influencing skin barrier dysfunction, notably through mutations like filaggrin, leading to increased exposure to harmful substances, immune reactions, and dry skin due to transepidermal water loss.<sup>21</sup> It is also characterized by a shift towards Th2 immunity, weakening the skin's barrier and innate immunity, and promoting IgE-mediated allergies and eosinophil activation, with T1, Th17, and Th22 immunity also contributing in chronic stages, alongside IgE autoimmunity and skin dysbiosis dominated by *S. aureus* during flare-ups.<sup>22,23</sup>

CUR has been extensively validated as an effective agent in controlling skin inflammation through multiple signaling pathways. A study demonstrates that CUR can effectively mitigate AD and related asthmatic symptoms in mice induced with ovalbumin, by normalizing skin pathology, suppressing inflammatory cell infiltration and cytokine expression, and restoring redox and NF- $\kappa$ B signaling balances.<sup>24</sup> Another study assessed the immunomodulatory effects of different concentrations of CUR on acetone-induced atopic dermatitis in female Albino rats, finding that a 5% CUR treatment most effectively promoted skin healing, maintained normal epidermal thickness without inflammatory cell presence, and significantly reduced Interleukin (IL) 13 levels, suggesting its superiority in treating rat dermatitis with enhanced therapeutic outcomes and minimal complications.<sup>25</sup> Kong et al also illustrate CUR's capability in reducing allergic inflammation in Rat Basophil Leukemia (RBL)-2H3 and human pre-basophil (KU812) cell lines by hindering cell degranulation, decreasing histamine and beta-hexosaminidase releases, reducing intracellular reactive oxygen species (ROS) production, and diminishing expressions of high-affinity IgE receptor (Fc $\epsilon$ RI) and pro-inflammatory cytokines such as IL-4 and IL-13, as well as inhibiting protein kinase C delta (PKC- $\delta$ ) translocation, effectively alleviating both Immunoglobulin E (IgE)-mediated and calcium ionophore A23187-stimulated allergic responses.<sup>26</sup> Nyoman et al also demonstrates that applying a 1% turmeric rhizome extract moisturizing nanoemulgel on BALB/c mice reduces atopic dermatitis (AD)-like skin lesions by lowering thymic stromal lymphopoietin (TSLP), IL-13, and IL-17 levels and improving dermatitis scores and histopathological features in a 2,4-dinitrochlorobenzene-induced model, though its effect on transepidermal water loss (TEWL) was not statistically significant.<sup>27</sup>

In clinical practice, Rawal et al concluded that Herbavate<sup>®</sup>, a topical polyherbal cream, significantly improved eczema symptoms with good local tolerance and minimal side effects, presenting it as an effective alternative management option for outpatient eczema treatment.<sup>28</sup> However, assessing the significance of the results is challenging due to the limited size of the control group, a significant dropout rate, and the potential influence of other ingredients in the cream. TOGNI et al suggested that Meriva<sup>®</sup>, a phytosome-based CUR delivery form, effectively reduces clinical signs of atopic dermatitis and lowers recurrence risk when used as an adjunct to standard management, demonstrating significant improvements in symptoms, skin health, and reduction in topical corticosteroid use.<sup>29</sup>

## Psoriasis

Psoriasis, a chronic immune-mediated inflammatory skin condition, impacts around 2–3% of the global population across all ages, particularly within the 16–22 and 55–60 age brackets.<sup>30,31</sup> It is marked by red, painful, scaly plaques that can emerge on different areas of the body, leading to substantial physical and psychological distress, and in severe cases, may even culminate in suicidal ideation.<sup>32,33</sup> An expanding corpus of research suggests that psoriasis ought to be regarded as a systemic condition due to its association with a heightened risk of numerous comorbidities, including cardiovascular diseases, metabolic syndrome, diabetes mellitus, and obesity, among others.<sup>34,35</sup> The onset of psoriasis is marked by

complex genetic, immunological, and environmental interactions that activate plasmacytoid dendritic cells, triggering dysregulated immune responses, excessive keratinocyte proliferation, and the production of proinflammatory cytokines such as tumor necrosis factor (TNF)- $\alpha$ , interferon (IFN)- $\gamma$ , IL-17, IL-22, IL-23, and IL-1 $\beta$ , which in turn stimulate further keratinocyte hyperproliferation and perpetuate chronic inflammation.<sup>36,37</sup>

CUR demonstrates significant efficacy and safety in treating psoriasis through various mechanisms, as evidenced by improved Psoriasis Area and Severity Index (PASI) scores, reduction in psoriatic dermatitis symptoms in mice, and decreased expression of inflammatory cytokines, suggesting that CUR, both as monotherapy and in combination with other treatments, is an effective strategy for managing psoriasis.<sup>38</sup> To be specific, Zhang et al, revealed that CUR effectively inhibits the NLRP3 inflammasome, reducing inflammation in a mouse model of psoriasis through topical application, with experiments showing significant reductions in NLRP3 expression and inflammation caused by IL-22 and IL-18, as well as a notable decrease in STAT3 phosphorylation.<sup>39</sup> Zhou et al demonstrated that progranulin (PGRN) plays a crucial role in the etiology of psoriasis and demonstrates that CUR, derived from turmeric, can mitigate the exacerbation of psoriasis-like skin lesions induced by PGRN deficiency in a mouse model, highlighting CUR's potential as a therapeutic agent by directly regulating keratinocyte proliferation and differentiation and reducing proinflammatory cytokine levels.<sup>40</sup> Cai et al also highlighted that CUR effectively mitigates psoriasis-like lesions in mice through oral administration, reducing PASI scores and inflammatory cytokines, enhancing IL-10 expression, and modulating gut microbiota, thereby suggesting CUR's potential as a promising treatment for psoriasis via regulating Th-17 related inflammatory factors and gut microbiome alterations.<sup>41</sup> They also concluded that CUR effectively reduces psoriasis-like lesions in mice, likely through inhibiting IL-6/STAT3 signaling pathways and decreasing the levels of TNF- $\alpha$ , IL-6, and the phosphorylation of STAT3 and its associated proteins, showcasing CUR's potential as a therapeutic agent for psoriasis.<sup>42</sup> Moreover, Skyvalidas et al also demonstrated that CUR significantly reduces the production of IFN- $\gamma$  and IL-17 in peripheral blood mononuclear cells from patients with psoriasis and psoriatic arthritis, indicating its anti-inflammatory and immunosuppressive effects, potentially through the modulation of STAT3 activation, thereby reinforcing its use as a dietary immunosuppressant in managing psoriatic disease.<sup>43</sup> Furthermore, Mousa et al demonstrated that a combination therapy of CUR and ustekinumab significantly alleviates symptoms in imiquimod-induced psoriasis in a rat model more effectively than ustekinumab monotherapy by synergistically reducing proinflammatory cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), IL-17, IL-12 subunit p40, and IL-23, and enhancing levels of antioxidant biomarkers, including superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT), indicating a promising, cost-effective approach for improving psoriasis treatment outcomes.<sup>44</sup>

Thus, the growing evidence supporting CUR's efficacy in psoriasis treatment reflects an encouraging trend towards blending traditional and modern therapeutic approaches. CUR's anti-inflammatory and immunomodulatory effects, particularly its influence on the IL-6/STAT3 pathway and the gut microbiome, highlight its potential as both an adjunct and an alternative to conventional psoriasis therapies. Despite promising results, the need for more comprehensive clinical trials remains to fully ascertain CUR's optimal usage, safety, and efficacy in psoriasis management. The integration of CUR into treatment regimens could offer a holistic solution to this complex disease, underscoring the importance of merging scientific research with traditional knowledge for improved patient outcomes.

## Chronic Wounds

Wound healing issues represent a significant and growing clinical challenge, with recent reports indicating that approximately one billion people worldwide suffer from chronic and acute wounds.<sup>45,46</sup> Especially, the chronic wound, defined as one that does not follow a timely and orderly repair process to achieve sustained anatomical and functional integrity and may last from 4 weeks to over 3 months due to factors like trauma, infection, pressure, diabetes, vascular disease, or radiation, affects approximately 2% of hospitalized patients globally, with older adults at the highest risk due to impaired healing related to aging, leading to a 70% recurrence rate and a 34% chance of being accompanied by infection.<sup>47,48</sup> Impaired wound healing can be categorized into local and systemic factors. Local factors include inadequate oxygen supply due to disturbed blood circulation and wound infections.<sup>49,50</sup> Systemic factors encompass a range of issues such as smoking, obesity, malnutrition, impaired mobility, diabetes, and gender, with hormones playing a significant role; estrogens positively and testosterone negatively affecting wound healing.<sup>51,52</sup>

The primary mechanism in the wound healing process involves controlling inflammation, which is crucial for optimal skin regeneration.<sup>53</sup> CUR plays a significant role in modulating inflammation by inhibiting the production of TNF- $\alpha$ , NF- $\kappa$ B and IL-1, which are crucial in inflammatory response regulation.<sup>54</sup> This action underscores the link between oxidation and inflammation in wound healing, highlighting CUR's potential as a therapeutic agent in managing inflammation to optimize wound healing processes.<sup>55</sup> Furthermore, a combination of quercetin and curcuminoids, particularly at a 3:1 ratio, significantly enhances wound healing by demonstrating synergistic antimicrobial activity against *S. aureus* and *P. aeruginosa*, superior antioxidant capacity, and promoting fibroblast migration, highlighting its potential as an effective formulation for acute and chronic wound care.<sup>56</sup> In addition, CUR modulates wound healing in a biphasic dose-response manner, stimulating at low doses via the induction of stress response pathways, thereby suggesting its potential in addressing age-related delays in wound healing.<sup>57</sup> Fei et al demonstrated that CUR mitigates hypertrophic scarring by inhibiting fibroblast proliferation, migration, and  $\alpha$ -SMA expression in a dose-dependent manner, primarily through suppression of the TGF- $\beta$ 1/Smad3 pathway and reduction of tissue inflammation, offering a scientific basis for its clinical application in scar treatment.<sup>58</sup> Wang et al also suggested that hypoxic preconditioning combined with CUR enhances the survival, cell cycle progression, and mitochondrial function of bone marrow mesenchymal stem cells (BMSCs), inhibits apoptosis, and promotes tissue repair, largely through the modulation of mitochondrial quality, oxidative phosphorylation, and the PGC-1 $\alpha$ /SIRT3/HIF-1 $\alpha$  signaling pathway, thereby accelerating cutaneous wound healing in a mice model and offering a promising approach for BMSCs-mediated tissue repair.<sup>59</sup>

In summary, CUR has been identified as a potent modulator of the wound healing process, with its multifaceted effects spanning the inflammatory, proliferative, and remodeling phases. Research indicates that by targeting these key phases, CUR effectively accelerates the wound healing timeline, showcasing its therapeutic potential in enhancing tissue repair.

## Skin Cancer

Skin cancer stands as the fifth most prevalent cancer today and is anticipated to outpace heart disease as the leading cause of death, posing the greatest barrier to increased life expectancy in the future.<sup>60</sup> With around 9.6 million cancer-related deaths and 18.1 million new cases in 2018, projections suggest a steady uptick in melanoma incidences, estimated at 6% for males and 4% for females in 2023, with expectations of continued growth over the next two decades.<sup>61,62</sup>

The development of skin cancer, particularly prevalent among fair-skinned populations, is significantly influenced by excessive UV radiation exposure, accounting for nearly 90% of cases.<sup>63</sup> UV radiation not only plays a crucial role in vitamin D synthesis and immune regulation but also in DNA damage, leading to skin cancer through mechanisms like the mitogen-activated protein kinase (MAPK) signaling pathway and immune system suppression.<sup>64,65</sup> The complex interplay of UV exposure, immune suppression, genetic mutations, and viral oncogenesis underscores the multifaceted nature of skin cancer development.<sup>66–69</sup>

CUR exhibits remarkable anti-cancer properties by selectively targeting tumor cells while sparing normal ones.<sup>70,71</sup> It can activate apoptosis through the caspase activation pathway, involving caspase-8, 3, and 9, and disrupts cell survival by downregulating anti-apoptotic proteins.<sup>72</sup> It also interferes with cell proliferation by targeting cyclin D1 and c-myc and enhances the function of tumor suppressor proteins such as p53 and p21.<sup>73</sup> Furthermore, it regulates death signaling via upregulation of death receptors DR4 and DR5, disrupts mitochondrial function to induce cell death, and modulates kinase signaling pathways.<sup>74,75</sup> The ability of CUR to selectively affect tumor cells over normal cells is notably due to the differential expression and susceptibility of these cells to the pathways CUR influences, making it a promising, multifaceted approach to cancer therapy with minimal side effects.

Regarding the skin cancer, Parashar et al introduced Compound A, a synthetic analog of CUR, demonstrating for the first time its selective apoptotic induction in melanoma cells, enhanced anti-cancer activity with tamoxifen, and compatibility with taxol and cisplatin, offering a promising direction for developing selective and effective melanoma treatments with minimal toxicity to noncancerous cells.<sup>76</sup> Szlasa et al demonstrated the efficacy of CUR as an anticancer agent in photodynamic therapy (PDT) for treating melanotic (A375) and amelanotic (C32) melanoma cell lines, showing significant cytotoxic effects and increased apoptosis and necrosis upon light irradiation, along with caspase-3 overexpression and DNA cleavage, although it lacks selectivity towards melanoma cells.<sup>77</sup> Manica revealed that CUR significantly reduces viability, induces apoptosis, inhibits migration, and increases oxidative stress in the metastatic

cutaneous melanoma cell line SK-MEL-28, through elevated ROS levels and activation of the caspase pathway, highlighting its potential as an adjuvant therapy for CM.<sup>78</sup> Tremmel et al demonstrated that a topical combination of ursolic acid and CUR significantly inhibits skin tumor promotion in mice more effectively than either compound alone by blocking critical signaling pathways like EGFR, NF- $\kappa$ B, and Src, reducing proliferation markers and inflammatory gene expression, thereby showcasing a synergistic, detailed mechanism of action for cancer chemoprevention.<sup>79</sup>

In summary, despite the escalating epidemiological burden of skin cancer, characterized by a marked increase in incidence and mortality rates, the investigation into CUR's utility as a therapeutic agent within the dermatological oncology landscape, particularly regarding melanoma, is conspicuously nascent. Preliminary investigations have elucidated CUR's multifaceted anticancer mechanisms, encompassing the induction of apoptosis, disruption of cell proliferation cycles, and the modulation of critical cellular signaling pathways in melanoma cell lines. However, the scope of research dedicated to leveraging CUR's potential for innovative, synergistic treatment modalities that promise minimal adverse effects remains embryonic, underscoring a significant gap in the current academic discourse on skin tumor therapeutics.

## Skin Infections

Skin and soft tissue infections (SSTIs), ranging from minor, superficial afflictions to severe, life-threatening conditions, are primarily incited by the ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species), known for their formidable antibiotic resistance.<sup>80</sup> Particularly, *Staphylococcus aureus* and *Pseudomonas aeruginosa*, frequently isolated from chronic wounds, present escalating challenges due to their growing resistance to topical antibiotics.<sup>81</sup> The management of SSTIs hinges on the infection's severity, location, and the patient's underlying conditions, distinguishing between simple and complicated infections, as well as suppurative and nonsuppurative types.<sup>82,83</sup> While community-acquired infections are predominantly due to methicillin-resistant *Staphylococcus aureus* (MRSA) and beta-hemolytic streptococcus, the microbial landscape is broadening, partly due to factors like diabetes, immune dysfunction, and environmental exposure.<sup>84-86</sup> Diagnosis relies on clinical assessment, with laboratory tests supporting uncertain cases or deep infection evaluations. Initial antimicrobial treatment is empirical, tailored to cover staphylococci and streptococci for simple infections, or a broader spectrum for complicated cases necessitating hospitalization and possibly surgical intervention.<sup>87</sup>

The role of CUR in treating skin infections, particularly in controlling wound infections, has been widely validated and recognized for its effectiveness.<sup>88</sup> For example, Paolillo et al demonstrated that antimicrobial photodynamic therapy (aPDT) using CUR gel and blue LED light, combined with alcohol-based artificial skin, significantly enhanced bacterial reduction and wound contraction in infected skin wounds of Wistar rats inoculated with *Staphylococcus aureus*, with the combination therapy showing the highest bacterial viability reduction and comparable wound contraction rates, highlighting the efficacy of integrating aPDT and artificial skin in accelerating wound healing and microbial control.<sup>89</sup> Krausz et al demonstrated that CUR, when encapsulated in silane-hydrogel nanoparticles (curc-np), exhibits significant potential as a topical therapy for wound infections, showcasing effective action against methicillin-resistant *Staphylococcus aureus* (MRSA) both in vitro and within a murine model of burn wounds.<sup>90</sup>

Research indicates that CUR disrupts the membranes of both Gram-negative and Gram-positive bacteria, causing cell leakage in various species including *E. coli*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, and *S. aureus*, albeit at elevated concentrations.<sup>91,92</sup> It employs mechanisms akin to traditional antibiotics, including membrane disruption, induction of cell division interruption, efflux pump inhibition, and Reactive Oxygen Species (ROS), to exterminate microorganisms.<sup>93</sup> Notably, CUR obstructs bacterial efflux pumps, a critical resistance mechanism, in pathogens like *Pseudomonas aeruginosa* and *S. aureus*.<sup>94</sup> It also targets the  $\alpha$ -hemolysin of *S. aureus*, preventing its self-assembly and subsequent hemolysis by binding and inhibiting conformational changes necessary for activity.<sup>95,96</sup> Furthermore, it suppresses genes involved in the carbohydrate metabolism and synthesis of Extracellular Polymeric Substances (EPS).<sup>97,98</sup> Additionally, CUR disrupts the bacterial cell division by interfering with FtsZ protein assembly, a strategy that has shown promise in targeting *S. aureus*.<sup>99</sup>

Furthermore, CUR has demonstrated antiviral activity against a variety of viruses. For example, studies have shown that low, non-toxic doses of CUR reduce the infectivity of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) both in vitro and in vivo, notably decreasing the expression of HSV-1 immediate early genes.<sup>100</sup> Similarly, CUR has been



found to reduce immediate early gene expression in human cytomegalovirus (HCMV) infections and exhibit varying effects on Epstein–Barr virus (EBV), inhibiting its reactivation in some studies while enhancing lytic reactivation in others.<sup>101,102</sup> Another study also concluded that various CUR derivatives exhibit excellent absorption, distribution, metabolism, excretion, and toxicity profiles. Based on these characteristics, the study recommends these derivatives as potential antiviral agents for treating Monkeypox and Smallpox virus infections.<sup>103</sup> In addition, CUR has shown significant anti-HPV effects in both laboratory and clinical settings.<sup>104</sup> It inhibits HPV-related oncogenes and restores tumor suppressor proteins like p53 and Rb.<sup>105</sup> Clinical trials, including a Phase II study, have demonstrated that CUR formulations can lead to approximately 80% clearance of HPV in affected patients.<sup>106</sup> Additionally, CUR enhances chemotherapy efficacy and increases radiation sensitivity in cancer cells, making it a promising candidate for HPV-related cancers.<sup>107</sup>

## Conclusions

In conclusion, the examination of CUR's multifunctional role across various dermatological conditions—ranging from atopic dermatitis, psoriasis, chronic wounds, skin cancer, to skin infections—highlights its significant therapeutic potential. Through an impressive array of mechanisms, including modulation of immune responses, anti-inflammatory actions, antimicrobial activities, and promotion of wound healing, CUR emerges as a versatile agent capable of addressing a wide spectrum of skin disorders. Its efficacy in mitigating inflammation, reducing cytokine levels, enhancing skin barrier functions, and inhibiting tumor cell proliferation, alongside its role in disrupting microbial cell structures and resisting antibiotic-resistant strains, underscores the compound's comprehensive utility in dermatology. Despite these promising findings, this review also points to the necessity for further research to establish optimized dosages, delivery methods, and long-term safety profiles of CUR in clinical settings. As such, while CUR presents a promising adjunct or alternative to traditional therapies, its integration into mainstream dermatological practice necessitates a balanced consideration of evidence-based efficacy, safety, and the potential for novel therapeutic formulations.

## Funding

There is no funding to report.

## Disclosure

The authors declare no conflicts of interest in this work.

## References

1. Sinikumpu SP, Jokelainen J, Haarala AK, Keränen MH, Keinänen-Kiukaanniemi S, Huilaja L. The High Prevalence of Skin Diseases in Adults Aged 70 and Older. *J Am Geriatr Soc.* 2020;68(11):2565–2571. doi:10.1111/jgs.16706
2. Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune-related skin diseases in 2019. *Expert Rev Clin Immunol.* 2020;16(2):155–166. doi:10.1080/1744666X.2020.1719833
3. Cortés H, Rojas-Márquez M, Del Prado-Audelo ML, Reyes-Hernández OD, González-Del Carmen M, Leyva-Gómez G. Alterations in mental health and quality of life in patients with skin disorders: a narrative review. *Int J Dermatol.* 2022;61(7):783–791. doi:10.1111/ijd.15852
4. Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin Disease in Children: effects on Quality of Life, Stigmatization, Bullying, and Suicide Risk in Pediatric Acne, Atopic Dermatitis, and Psoriasis Patients. *Children.* 2021;8(11):1057. doi:10.3390/children8111057
5. Rathore S, Mukim M, Sharma P, et al. Curcumin: a review for health benefits. *Int J Res Rev Appl Sci.* 2020;7(1):273–290.
6. Vogel A, Pelletier J. Examen chimique de la racine de Curcuma. *J Pharm.* 1815;1:289–300.
7. Jeon JH, Jeong SA, Park DS, Park HH, Shin SW, Oh HW. Disruptive Effects of Two Curcuminoids (Demethoxycurcumin and Bisdemethoxycurcumin) on the Larval Development of *Drosophila melanogaster*. *Insects.* 2023;14(12):959. doi:10.3390/insects14120959
8. Peng Y, Ao M, Dong B, et al. Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: status, Limitations and Countermeasures. *Drug Des Devel Ther.* 2021;15:4503–4525. doi:10.2147/DDDT.S327378
9. Ghareghomi S, Rahban M, Moosavi-Movahedi Z, Habibi-Rezaei M, Saso L, Moosavi-Movahedi AA. The Potential Role of Curcumin in Modulating the Master Antioxidant Pathway in Diabetic Hypoxia-Induced Complications. *Molecules.* 2021;26(24):7658. doi:10.3390/molecules26247658
10. Hani U, Gowda BHJ, Siddiqua A, Wahab S. Herbal approach for treatment of cancer using curcumin as an anticancer agent: a review on novel drug delivery systems. *J Mol.* 2023.
11. Aminnezhad S, Zonobian MA. Curcumin and their derivatives with anti-inflammatory, neuroprotective, anticancer, and antimicrobial activities: a review. *Micro Nano Bio.* 2023.
12. Liczbiński P, Michałowicz J, Bukowska B. Molecular mechanism of curcumin action in signaling pathways: review of the latest research. *Phytother Res.* 2020;34(8):1992–2005. doi:10.1002/ptr.6663

13. Vollono L, Falconi M, Gaziano R, et al. Potential of Curcumin in Skin Disorders. *Nutrients*. 2019;11(9). doi:10.3390/nu11092169
14. Hegde M, Girisa S, BharathwajChetty B, Vishwa R, Kunnumakkara AB. Curcumin Formulations for Better Bioavailability: what We Learned from Clinical Trials Thus Far? *ACS Omega*. 2023;8(12):10713–10746. doi:10.1021/acsomega.2c07326
15. Jiang Z, Gan J, Wang L, Lv C. Binding of curcumin to barley protein Z improves its solubility, stability and bioavailability. *Food Chem*. 2023;399:133952. doi:10.1016/j.foodchem.2022.133952
16. Panahi Y, Fazlollahzadeh O, Atkin SL, et al. Evidence of curcumin and curcumin analogue effects in skin diseases: a narrative review. *J Cell Physiol*. 2019;234(2):1165–1178. doi:10.1002/jcp.27096
17. Mata da IR, Menezes RCR, Faccioli LS, Bandeira KK, Bosco SMD. Benefits of turmeric supplementation for skin health in chronic diseases: a systematic review. *Crit Rev Food Sci Nutr*. 2021;61(20):3421–3435. doi:10.1080/10408398.2020.1798353
18. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. *Int J Mol Sci*. 2021;22(8):4130. doi:10.3390/ijms22084130
19. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. *Ann Allergy Asthma Immunol*. 2021;126(1):21–31. doi:10.1016/j.anai.2020.08.016
20. Tian J, Zhang D, Yang Y, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. *Br J Dermatol*. 2023;190(1):55–61. doi:10.1093/bjd/ljad339
21. Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. *J Allergy Clin Immunol*. 2023;151(5):1145–1154. doi:10.1016/j.jaci.2022.10.023
22. David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: pathophysiology. *Adv Exp Med Biol*. 2017;1027:21–37.
23. Yamaguchi HL, Yamaguchi Y, Peeva E. Role of Innate Immunity in Allergic Contact Dermatitis: an Update. *Int J Mol Sci*. 2023;24(16):12975. doi:10.3390/ijms241612975
24. Sharma S, Sethi GS, Naura AS. Curcumin Ameliorates Ovalbumin-Induced Atopic Dermatitis and Blocks the Progression of Atopic March in Mice. *Inflammation*. 2020;43(1):358–369. doi:10.1007/s10753-019-01126-7
25. Al Fatlawy A, Mlaghee SM. Therapeutic effect of curcumin on dermatitis induced by acetone in female rats. *Kufa J Vet Med Sci*. 2023;14(2):1–8. doi:10.36326/kjvs/2023/v14i212138
26. Kong ZL, Sudirman S, Lin HJ, Chen WN. In vitro anti-inflammatory effects of curcumin on mast cell-mediated allergic responses via inhibiting FcεRI protein expression and protein kinase C delta translocation. *Cytotechnology*. 2020;72(1):81–95. doi:10.1007/s10616-019-00359-6
27. Suryawati N, Wardhana M, Bakta IM, Jawi M. Moisturizing Nanoemulgel of Turmeric (*Curcuma longa*) Rhizome Extract Ameliorates Atopic Dermatitis-like Skin Lesions in Mice Model through Thymic Stromal Lymphopoietin, Interleukin-13, and Interleukin-17. *Biomol Health Sci J*. 2022;5(2):81. doi:10.4103/bhsj.bhsj\_26\_2
28. Rawal RC, Shah BJ, Jayaraaman AM, Jaiswal V. Clinical evaluation of an Indian polyherbal topical formulation in the management of eczema. *J Altern Complement Med*. 2009;15(6):669–672. doi:10.1089/acm.2008.0508
29. Togni S, Riva A, Maramaldi G, Cesarone M, Belcaro G Oral curcumin (Meriva®) reduces symptoms and recurrence rates in subjects with atopic dermatitis. Available from: [https://www.researchgate.net/profile/Stefano-Togni/publication/353215820\\_Oral\\_curcumin\\_MerivaR\\_reduces\\_symptoms\\_and\\_recurrence\\_rates\\_in\\_subjects\\_with\\_atopic\\_dermatitis/links/616309761eb5da761e751ff0/Oral-curcumin-MerivaR-reduces-symptoms-and-recurrence-rates-in-subjects-with-atopic-dermatitis.pdf](https://www.researchgate.net/profile/Stefano-Togni/publication/353215820_Oral_curcumin_MerivaR_reduces_symptoms_and_recurrence_rates_in_subjects_with_atopic_dermatitis/links/616309761eb5da761e751ff0/Oral-curcumin-MerivaR-reduces-symptoms-and-recurrence-rates-in-subjects-with-atopic-dermatitis.pdf). Accessed May 7, 2024.
30. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. *Int J Mol Sci*. 2023;24(17). doi:10.3390/ijms241713313
31. Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: results and Insights From the Global Burden of Disease 2019 Study. *Front Med*. 2021;8:743180. doi:10.3389/fmed.2021.743180
32. Wintermann GB, Bierling AL, Peters EMJ, Abraham S, Beissert S, Weidner K. Psychosocial stress affects the change of mental distress under dermatological treatment-A prospective cohort study in patients with psoriasis. *Stress Health*. 2023;40(1). doi:10.1002/smi.3263
33. Boswell ND, Cook MK, Balogh EA, Feldman SR. The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review. *Arch Dermatol Res*. 2023;315(4):699–706. doi:10.1007/s00403-022-02420-5
34. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? *Br J Dermatol*. 2020;182(4):840–848. doi:10.1111/bjd.18245
35. Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: from Pathophysiology to Novel Therapeutic Approaches. *Biomedicine*. 2021;9(11):1511. doi:10.3390/biomedicine9111511
36. Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. *Exp Dermatol*. 2021;30(8):1156–1166. doi:10.1111/exd.14332
37. Sabri SA, Ibraheem S. A study correlation between levels IL-15, IL-23 and TNF-α in a sample of Iraqi psoriasis patients. *J Pure Appl Sci*. 2024. doi:10.30526/37.1.3148
38. Zhang S, Wang J, Liu L, et al. Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms. *Front Pharmacol*. 2022;13:903160. doi:10.3389/fphar.2022.903160
39. Zhang J, Ma Y, Li W. Curcumin reduces inflammation in mice with the psoriasis model by inhibiting NLRP3 inflammatory bodies. *Cell Mol Biol*. 2022;67(6):48–54. doi:10.14715/cmb/2021.67.6.7
40. Zhou T, Zhang S, Zhou Y, et al. Curcumin alleviates imiquimod-induced psoriasis in progranulin-knockout mice. *Eur J Pharmacol*. 2021;909:174431. doi:10.1016/j.ejphar.2021.174431
41. Cai Z, Wang W, Zhang Y, Zeng Y. Curcumin alleviates imiquimod-induced psoriasis-like inflammation and regulates gut microbiota of mice. *Immun Inflamm Dis*. 2023;11(8):e967. doi:10.1002/iid3.967
42. Cai Z, Zeng Y, Liu Z, Zhu R, Wang W. Curcumin Alleviates Epidermal Psoriasis-Like Dermatitis and IL-6/STAT3 Pathway of Mice. *Clin Cosmet Invest Dermatol*. 2023;16:2399–2408. doi:10.2147/CCID.S423922
43. Skyvalidas DN, Mavropoulos A, Tsiogkas S, et al. Curcumin mediates attenuation of pro-inflammatory interferon γ and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant. *Nutr Res*. 2020;75:95–108. doi:10.1016/j.nutres.2020.01.005
44. Mousa AM, Alhumaydhi FA, Abdellatif AAH, et al. Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects. *Cutan Ocul Toxicol*. 2022;41(1):33–42. doi:10.1080/15569527.2021.2003377
45. Carter MJ, DaVanzo J, Haught R, Nussgart M, Cartwright D, Fife CE. Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019. *J Med Econ*. 2023;26(1):894–901. doi:10.1080/13696998.2023.2232256

46. Garraud O, Hozzein WN, Badr G. Wound healing: time to look for intelligent, “natural” immunological approaches? *BMC Immunol.* **2017**;18 (Suppl 1):23. doi:10.1186/s12865-017-0207-y
47. Yao Z, Niu J, Cheng B. Prevalence of Chronic Skin Wounds and Their Risk Factors in an Inpatient Hospital Setting in Northern China. *Adv Skin Wound Care.* **2020**;33(9):1–10. doi:10.1097/01.ASW.0000694164.34068.82
48. Spampinato SF, Caruso GI, De Pasquale R, Sortino MA, Merlo S. The Treatment of Impaired Wound Healing in Diabetes: looking among Old Drugs. *Pharmaceuticals.* **2020**;13(4):60. doi:10.3390/ph13040060
49. Gushiken LFS, Beserra FP, Bastos JK, Jackson CJ, Pellizzon CH. Cutaneous Wound Healing: an Update from Physiopathology to Current Therapies. *Life.* **2021**;11(7):665. doi:10.3390/life11070665
50. Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound Healing: a Cellular Perspective. *Physiol Rev.* **2019**;99(1):665–706. doi:10.1152/physrev.00067.2017
51. Raeder K, Jachan DE, Müller-Werdan U, Lahmann NA. Prevalence and risk factors of chronic wounds in nursing homes in Germany: a Cross-Sectional Study. *Int Wound J.* **2020**;17(5):1128–1134. doi:10.1111/iwj.13486
52. De Paiva Gonçalves V, Steffens JP, Junior CR. ... testosterone supplementation improves granulation tissue maturation through angiogenesis in the early phase of a cutaneous wound healing model in rats. *Inflammation.* **2022**;71(4):473–483. doi:10.1007/s00011-022-01553-7
53. Hong YK, Chang YH, Lin YC, Chen B, Guevara BEK, Hsu CK. Inflammation in Wound Healing and Pathological Scarring. *Adv Wound Care.* **2023**;12(5):288–300. doi:10.1089/wound.2021.0161
54. Uddin SJ, Hasan MF, Afroz M, et al. Curcumin and its Multi-target Function Against Pain and Inflammation: an Update of Pre-clinical Data. *Curr Drug Targets.* **2021**;22(6):656–671. doi:10.2174/1389450121666200925150022
55. Fernández-Lázaro D, Mielgo-Ayuso J, Seco Calvo J, Córdova Martínez A, Caballero García A, Fernandez-Lazaro CI. Modulation of Exercise-Induced Muscle Damage, Inflammation, and Oxidative Markers by Curcumin Supplementation in a Physically Active Population: a Systematic Review. *Nutrients.* **2020**;12(2):501. doi:10.3390/nu12020501
56. Chittasupho C, Manthaisong A, Okonogi S, Tadtong S, Samee W. Effects of Quercetin and Curcumin Combination on Antibacterial, Antioxidant, In Vitro Wound Healing and Migration of Human Dermal Fibroblast Cells. *Int J Mol Sci.* **2021**;23(1):142. doi:10.3390/ijms23010142
57. Demirovic D, Rattan SIS. Curcumin induces stress response and hormetically modulates wound healing ability of human skin fibroblasts undergoing ageing in vitro. *Biogerontology.* **2011**;12(5):437–444. doi:10.1007/s10522-011-9326-7
58. Fei H, Qian Y, Pan T, Wei Y, Hu Y. Curcumin alleviates hypertrophic scarring by inhibiting fibroblast activation and regulating tissue inflammation. *J Cosmet Dermatol.* **2024**;23(1):227–235. doi:10.1111/jocd.15905
59. Wang X, Shen K, Wang J, et al. Hypoxic preconditioning combined with curcumin promotes cell survival and mitochondrial quality of bone marrow mesenchymal stem cells, and accelerates cutaneous wound healing via PGC-1 $\alpha$ /SIRT3/HIF-1 $\alpha$  signaling. *Free Radic Biol Med.* **2020**;159:164–176. doi:10.1016/j.freeradbiomed.2020.07.023
60. Hasan N, Nadaf A, Imran M, et al. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. *Mol Cancer.* **2023**;22(1):168. doi:10.1186/s12943-023-01854-3
61. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin.* **2023**;73(1):17–48. doi:10.3322/caac.21763
62. Tiwari N, Kumar D, Priyadarshani A, et al. Recent progress in polymeric biomaterials and their potential applications in skin regeneration and wound care management. *J Drug Deliv Sci Technol.* **2023**;82:104319.
63. Islam MR, Akash S, Rauf A, Sharma R. Skin cancer from the perspective of public health concerns: etiology, transmission, diagnosis, treatment, and complications - correspondence. *Ann Med Surg Lond.* **2023**;85(5):2266–2267. doi:10.1097/MS9.0000000000000662
64. Tanveer MA, Rashid H, Nazir LA, et al. Trigonelline, a plant derived alkaloid prevents ultraviolet-B-induced oxidative DNA damage in primary human dermal fibroblasts and BALB/c mice via modulation of phosphoinositide 3-kinase-Akt-Nrf2 signalling axis. *Exp Gerontol.* **2023**;171:112028. doi:10.1016/j.exger.2022.112028
65. Elkoshi N, Parikh S, Malcov-Brog H, et al. Ataxia telangiectasia mutated signaling delays skin pigmentation upon UV exposure by mediating MITF function toward DNA repair mode. *J Invest Dermatol.* **2023**;143(12):2494–2506.e4. doi:10.1016/j.jid.2023.03.1686
66. Nlekwwuwa PR Regulation of BubR1 by ultraviolet radiation: implications in skin cancer; **2023**. Available from: <https://search.proquest.com/openview/3edee9ada397bc30a9168554560d19d4/1?pq-origsite=gscholar&cbl=18750&diss=y>. Accessed May 7, 2024.
67. Oparaugo NC, Ouyang K, Nguyen NPN, Nelson AM, Agak GW. Human Regulatory T Cells: understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers. *Int J Mol Sci.* **2023**;24(2):1527. doi:10.3390/ijms24021527
68. Pfeifer GP. Mechanisms of UV-induced mutations and skin cancer. *Genome Instab Dis.* **2020**;1(3):99–113. doi:10.1007/s42764-020-00009-8
69. Becerril S, Corchado-Cobos R, García-Sancha N, et al. Viruses and Skin Cancer. *Int J Mol Sci.* **2021**;22(10):5399. doi:10.3390/ijms22105399
70. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? *AAPS J.* **2009**;11(3):495–510. doi:10.1208/s12248-009-9128-x
71. Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. *Biofactors.* **2021**;47(6):914–932. doi:10.1002/biof.1776
72. Xiang L, He B, Liu Q, et al. Antitumor effects of curcumin on the proliferation, migration and apoptosis of human colorectal carcinoma HCT-116 cells. *Oncol Rep.* **2020**;44(5):1997–2008. doi:10.3892/or.2020.7765
73. Li P, Pu S, Lin C, et al. Curcumin selectively induces colon cancer cell apoptosis and S cell cycle arrest by regulates Rb/E2F/p53 pathway. *J Mol Struct.* **2022**;1263:133180. doi:10.1016/j.molstruc.2022.133180
74. Obaidi I, Cassidy H, Gaspar VI, et al. Curcumin Sensitizes Kidney Cancer Cells to TRAIL-Induced Apoptosis via ROS Mediated Activation of JNK-CHOP Pathway and Upregulation of DR4. *Biology.* **2020**;9(5):92. doi:10.3390/biology9050092
75. Yu C, Yang B, Najafi M. Targeting of cancer cell death mechanisms by curcumin: implications to cancer therapy. *Basic Clin Pharmacol Toxicol.* **2021**;129(6):397–415. doi:10.1111/bcpt.13648
76. Parashar K, Sood S, Mehaidli A, et al. Evaluating the Anti-cancer Efficacy of a Synthetic Curcumin Analog on Human Melanoma Cells and Its Interaction with Standard Chemotherapeutics. *Molecules.* **2019**;24(13):2483. doi:10.3390/molecules24132483
77. Szlasa W, Supplitt S, Drag-Zalesińska M, et al. Effects of curcumin based PDT on the viability and the organization of actin in melanotic (A375) and amelanotic melanoma (C32) - in vitro studies. *Biomed Pharmacother.* **2020**;132(110883):110883. doi:10.1016/j.biopha.2020.110883
78. Manica D, Silva da GB. Curcumin promotes apoptosis of human melanoma cells by caspase 3. *Cell Biochem Funct.* **2023**;41(8):1295–1304. doi:10.1002/cbf.3863



79. Tremmel L, Rho O, Slaga TJ, DiGiovanni J. Inhibition of skin tumor promotion by TPA using a combination of topically applied ursolic acid and curcumin. *Mol. Carcinog.* **2019**;58(2):185–195. doi:10.1002/mc.22918
80. Vale de Macedo GHR, Costa GDE, Oliveira ER, et al. Interplay between ESKAPE Pathogens and Immunity in Skin Infections: an Overview of the Major Determinants of Virulence and Antibiotic Resistance. *Pathogens.* **2021**;10(2):148. doi:10.3390/pathogens10020148
81. Leong HN, Kurup A, Tan MY, Kwa ALH, Liao KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. *Infect Drug Resist.* **2018**;11:1959–1974. doi:10.2147/IDR.S172366
82. Hatlen TJ, Miller LG. Staphylococcal Skin and Soft Tissue Infections. *Infect Dis Clin North Am.* **2021**;35(1):81–105. doi:10.1016/j.idc.2020.10.003
83. Jabbour JF, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. *Curr Opin Infect Dis.* **2020**;33(2):146–154.
84. Allaw F, Zakhour J, Kanj SS. Community-acquired skin and soft-tissue infections in people who inject drugs. *Curr Opin Infect Dis.* **2023**;36(2):67–73. doi:10.1097/QCO.0000000000000902
85. Alizai Q, Haseeb A, Hamayun S, et al. Community-Acquired Skin and Soft Tissue Infections: epidemiology and Management in Patients Presenting to the Emergency Department of a Tertiary Care Hospital. *Cureus.* **2023**;15(1):e34379. doi:10.7759/cureus.34379
86. Morgan Bustamante BL, Fejerman L, May L, Martínez-López B. Community-acquired Staphylococcus aureus skin and soft tissue infection risk assessment using hotspot analysis and risk maps: the case of California emergency departments. *BMC Public Health.* **2024**;24(1):123. doi:10.1186/s12889-023-17336-6
87. Duane TM, Huston JM, Collom M, et al. Surgical Infection Society 2020 Updated Guidelines on the Management of Complicated Skin and Soft Tissue Infections. *Surg Infect.* **2021**;22(4):383–399.
88. Kumari M, Nanda DK. Potential of Curcumin nanoemulsion as antimicrobial and wound healing agent in burn wound infection. *Burns.* **2023**;49(5):1003–1016. doi:10.1016/j.burns.2022.10.008
89. Paolillo FR, Rodrigues PGS, Bagnato VS, Alves F, Pires L, Corazza AV. The effect of combined curcumin-mediated photodynamic therapy and artificial skin on Staphylococcus aureus-infected wounds in rats. *Lasers Med Sci.* **2021**;36(6):1219–1226. doi:10.1007/s10103-020-03160-6
90. Krausz AE, Adler BL, Cabral V, et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. *Nanomedicine.* **2015**;11(1):195–206. doi:10.1016/j.nano.2014.09.004
91. Kumar P, Saha T, Behera S, Gupta S, Das S, Mukhopadhyay K. Enhanced efficacy of a Cu<sup>2+</sup> complex of curcumin against Gram-positive and Gram-negative bacteria: attributes of complex formation. *J Inorg Biochem.* **2021**;222:111494. doi:10.1016/j.jinorgbio.2021.111494
92. Duan S, Zhao X, Su Z, Wang C, Lin Y. Layer-by-Layer Decorated Nanoscale ZIF-8 with High Curcumin Loading Effectively Inactivates Gram-Negative and Gram-Positive Bacteria. *ACS Appl Bio Mater.* **2020**;3(6):3673–3680. doi:10.1021/acsabm.0c00300
93. Zheng D, Huang C, Huang H, et al. Antibacterial Mechanism of Curcumin: a Review. *Chem Biodivers.* **2020**;17(8):e2000171. doi:10.1002/cbdv.202000171
94. Zahmatkesh H, Mirpour M, Zamani H, Rasti B. Effect of samarium oxide nanoparticles fabricated by curcumin on efflux pump and virulence genes expression in MDR Pseudomonas aeruginosa and staphylococcus aureus. *J Cluster Sci.* **2022**. doi:10.1007/s10876-022-02274-x
95. Olchowik-Grabarek E, Sekowski S, Bitiucki M, et al. Inhibition of interaction between Staphylococcus aureus  $\alpha$ -hemolysin and erythrocytes membrane by hydrolysable tannins: structure-related activity study. *Sci Rep.* **2020**;10(1):11168. doi:10.1038/s41598-020-68030-1
96. Singh M, Rupesh N, Pandit SB, Chattopadhyay K. Curcumin Inhibits Membrane-Damaging Pore-Forming Function of the  $\beta$ -Barrel Pore-Forming Toxin Vibrio cholerae Cytolysin. *Front Microbiol.* **2021**;12:809782. doi:10.3389/fmicb.2021.809782
97. Li B, Li X, Lin H, Zhou Y. Curcumin as a Promising Antibacterial Agent: effects on Metabolism and Biofilm Formation in S. mutans. *Biomed Res Int.* **2018**;2018:4508709. doi:10.1155/2018/4508709
98. Harisha CB, Meena KK, Rane J, et al. Bacterial derived biopolymer to alleviate nutrient stress and yield enhancement in turmeric (*Curcuma longa* L.) by mediating physiology and rhizosphere microbes on poor soils of semi-arid tropics. *Arch Acker Pflanzenbau Bodenkd.* **2023**;69(13):2645–2662.
99. Rai D, Singh JK, Roy N, Panda D. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochem J.* **2008**;410(1):147–155. doi:10.1042/BJ20070891
100. Suttithumsatid W, Panichayupakaranant P. Herbal drugs for the management and treatment of herpes simplex infections. *Herbal Drugs Management Infectious Dis.* **2022**;359–388. doi:10.1002/9781119818779.ch13
101. Šudomová M, Hassan STS. Nutraceutical Curcumin with Promising Protection against Herpesvirus Infections and Their Associated Inflammation: mechanisms and Pathways. *Microorganisms.* **2021**;9(2):292. doi:10.3390/microorganisms9020292
102. Praditya D, Kirchhoff L, Brüning J, Rachmawati H, Steinmann J, Steinmann E. Anti-infective Properties of the Golden Spice Curcumin. *Front Microbiol.* **2019**;10:912. doi:10.3389/fmicb.2019.00912
103. Akash S, Hossain A, Hossain MS, et al. Anti-viral drug discovery against monkeypox and smallpox infection by natural curcumin derivatives: a Computational drug design approach. *Front Cell Infect Microbiol.* **2023**;13:1157627. doi:10.3389/fcimb.2023.1157627
104. Mishra A, Das BC. Curcumin as an anti-human papillomavirus and anti-cancer compound. *Future Oncol.* **2015**;11(18):2487–2490. doi:10.2217/fon.15.166
105. Maher DM, Bell MC, O'Donnell EA, Gupta BK, Jaggi M, Chauhan SC. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. *Mol. Carcinog.* **2011**;50(1):47–57. doi:10.1002/mc.20695
106. Basu P, Dutta S, Begum R, et al. Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. *Asian Pac J Cancer Prev.* **2013**;14(10):5753–5759. doi:10.7314/APJCP.2013.14.10.5753
107. Zhang X, Zhu L, Wang X, Zhang H, Wang L, Xia L. Basic research on curcumin in cervical cancer: progress and perspectives. *Biomed Pharmacother.* **2023**;162:114590. doi:10.1016/j.biopha.2023.114590

**Clinical, Cosmetic and Investigational Dermatology****Dovepress****Publish your work in this journal**

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>